Navigation Links
PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
Date:10/23/2008

y and development strategy, Dr. Alberto Grignolo has helped numerous companies manage business risk by promoting effective regulatory strategies and relationships with regulators. Leading a global team of experts at PAREXEL Consulting, Dr. Grignolo oversees the management of regulatory submissions for clients with Regulatory Authorities worldwide. Dr. Grignolo has been an advocate for progress in personalized drug development, and has helped the industry recognize emerging opportunities to deliver safe and effective medicines to the right patients. Prior to joining PAREXEL, Dr. Grignolo served as President of FIDIA Pharmaceutical Corporation, and held management positions in regulatory affairs at Smith Kline & French Laboratories. He has served as an adviser to the Institute of Medicine of the National Academy of Sciences on human subject protection in clinical trials. He is currently a member of the Executive Committee of the Clinical Trials Transformation Initiative (CTTI). Dr. Grignolo has served as a leader of several industry organizations, including as Chairman of RAPS and on the Board of Directors for DIA. Dr. Grignolo holds a Ph.D. in Psychology from the University of North Carolina at Chapel Hill and a B.S. degree from Duke University. He completed postdoctoral work in neuropharmacology at Duke University Medical Center. He is currently Adjunct Associate Professor at the Massachusetts College of Pharmacy and Health Sciences.

Good Clinical Practice Journal (GCPj) (http://www.gcpj.com) addresses the regulatory, strategic, and clinical issues that directly impact clinical studies globally.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
2. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
3. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
4. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
5. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
6. PAREXEL Closes the Acquisition of ClinPhone
7. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
8. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
9. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
10. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
11. PAREXEL Expands Global Clinical Logistics Capabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC ... to the 2015 AACC Annual Meeting & Clinical ... from July 26–30. The meeting showcased revolutionary advancements ... the ability of healthcare providers to diagnose patients ... effective medical treatment. As of ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... -- HIGHLIGHTS:Q2 2015 Results (all changes are ... sales were $697 million compared to $701 million in ... 8%, and changes in foreign currency exchange rates decreased ... , By business unit, organic sales growth was ... SAFC Commercial. , Reported diluted EPS was $0.98 ...
(Date:7/29/2015)... PARIS , July 30, 2015 ... de la santé, publie ses résultats pour le ... Brandicourt commente les résultats. Visionner ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire ... - Moteurs de croissance ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... as a "biotech hotspot," this time in e-mail newsletter ... state's profile and is just what the biotech industry ... list of five hotspots were California, Maryland, New Jersey ... the list, told Forbes it was a subjective ranking ...
... Innovation Center Back in the mid-1980s, encouraging economic ... public utilities. But then Plant Sites & Parks magazine ... U.S. , ,Jim Mohrbacher, who worked in corporate ... and mentioned to a colleague that he thought Madison ...
... Corporation is expanding into nearly 4,000 square feet of ... few minutes south of Madison. , ,Symphony CEO Ravi Kalla ... to be customized to make it possible to serve clients ... and video conferencing capabilities to allow contact with a hundred ...
Cached Biology Technology:Utilities help switch on economic development 2Utilities help switch on economic development 3Utilities help switch on economic development 4
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 /PRNewswire/ ... and services for gene function analysis and biomarker ... Guide RNA (sgRNA) Knockout Library targeting all human ... specifically and permanently "knock out" a gene,s function. ... provides a high throughput screening tool so that ...
(Date:7/21/2015)... 21, 2015 Today, ZTE announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... smartphone manufacturer in China and we are ... 5 for Axon , its ...
(Date:7/13/2015)... 13, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND ... and secure method to make payments.  With this ... introduced with its groundbreaking voice-direct payment patent application, ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... adult male sea turtles ( Caretta caretta ) using ... the potential risks posed to this threatened species by ... Toxicology and Chemistry , examines the different levels of ... turtles. "The risks posed by persistent organic pollutants ...
... BUFFALO, NY -- Exposure to air pollution early in life ... may alter her DNA and may be associated with premenopausal ... Buffalo have shown. The findings indicated that higher air ... increase levels of E-cadherin, a protein important to the adhesion ...
... in German . , Is the vacuum-packed ... not tell the whole story. And the "best-before" date is ... have added to the uncertainty, and the customer him- or ... This is an area in which a sensor film developed ...
Cached Biology News:Satellite tracking of sea turtles reveals potential threat posed by manmade chemicals 2Air pollution exposure affects chances of developing premenopausal breast cancer 2Rotten meat doesn't stand a chance 2
...
...
... I-96 Plate can be used either in ... large-scale (i.e., 96-well) purification of DNA and/or ... unique silica-based matrix make it perfect for ... RNA in = 10 l eluate per ...
Request Info...
Biology Products: